Stockholm April 27, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for 2022 has been published.
The Annual Report, which is attached, can also be downloaded from the company’s website, www.bioarctic.se/en (Investors/Financial reports and presentations).
For further information, please contact:
Jan Mattsson, CFO,
Phone: + 46 70 352 27 72
Oskar Bosson, Vice President Investor Relations & Communications
Phone: +46 70 410 71 80
This information is information that BioArctic AB (publ) is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication at 08:00 am CET on April 27, 2023.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and ALS. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic’s Class B share is listed on Nasdaq Stockholm Large Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.